The US Food and Drug Administration has approved ICIs for the first-line treatment of NSCLC with specific PD-L1 expression limits (pembrolizumab: TPS ≥ 1%, atezolizumab: TPS ≥ 50%, cemiplimab-rwlc: TPS ≥ 50%), based on previous results of phase 3 randomized controlled trials [12, 15, 18]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.